The antitumor activity of mobocertinib was demonstrated in an international phase 1/2 study that enrolled platinum-pretreated patients with NSCLC harboring EGFR exon 20 insertion mutations; the ORR was 28% (95% CI 20–37) and the IRC-assessed median PFS was 7.3 months (95% CI 5.5–9.2) [29]. This evidence concerns the gene EGFR and non-small cell lung carcinoma.